Biological and therapeutic implications of a unique subtype of NPM1 mutated AML
Molecular heterogeneity of acute myeloid leukaemia (AML) across patients is a major challenge for prognosis and therapy. Here, the authors show that NPM1 mutated AML is a heterogeneous class, consisting of two subtypes which exhibit distinct molecular characteristics, differentiation state, patient...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a1a1fb4ad66d4a54b1ec1c09785a2551 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:a1a1fb4ad66d4a54b1ec1c09785a2551 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:a1a1fb4ad66d4a54b1ec1c09785a25512021-12-02T10:52:48ZBiological and therapeutic implications of a unique subtype of NPM1 mutated AML10.1038/s41467-021-21233-02041-1723https://doaj.org/article/a1a1fb4ad66d4a54b1ec1c09785a25512021-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-21233-0https://doaj.org/toc/2041-1723Molecular heterogeneity of acute myeloid leukaemia (AML) across patients is a major challenge for prognosis and therapy. Here, the authors show that NPM1 mutated AML is a heterogeneous class, consisting of two subtypes which exhibit distinct molecular characteristics, differentiation state, patient survival and drug response.Arvind Singh MerEmily M. HeathSeyed Ali Madani TonekaboniNergiz Dogan-ArtunSisira Kadambat NairAlex MurisonLaura Garcia-PratLiran ShlushRose HurrenVeronique VoisinGary D. BaderCorey NislowMattias RantalainenSoren LehmannMark GowerCynthia J. GuidosMathieu LupienJohn E. DickMark D. MindenAaron D. SchimmerBenjamin Haibe-KainsNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-13 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Science Q |
spellingShingle |
Science Q Arvind Singh Mer Emily M. Heath Seyed Ali Madani Tonekaboni Nergiz Dogan-Artun Sisira Kadambat Nair Alex Murison Laura Garcia-Prat Liran Shlush Rose Hurren Veronique Voisin Gary D. Bader Corey Nislow Mattias Rantalainen Soren Lehmann Mark Gower Cynthia J. Guidos Mathieu Lupien John E. Dick Mark D. Minden Aaron D. Schimmer Benjamin Haibe-Kains Biological and therapeutic implications of a unique subtype of NPM1 mutated AML |
description |
Molecular heterogeneity of acute myeloid leukaemia (AML) across patients is a major challenge for prognosis and therapy. Here, the authors show that NPM1 mutated AML is a heterogeneous class, consisting of two subtypes which exhibit distinct molecular characteristics, differentiation state, patient survival and drug response. |
format |
article |
author |
Arvind Singh Mer Emily M. Heath Seyed Ali Madani Tonekaboni Nergiz Dogan-Artun Sisira Kadambat Nair Alex Murison Laura Garcia-Prat Liran Shlush Rose Hurren Veronique Voisin Gary D. Bader Corey Nislow Mattias Rantalainen Soren Lehmann Mark Gower Cynthia J. Guidos Mathieu Lupien John E. Dick Mark D. Minden Aaron D. Schimmer Benjamin Haibe-Kains |
author_facet |
Arvind Singh Mer Emily M. Heath Seyed Ali Madani Tonekaboni Nergiz Dogan-Artun Sisira Kadambat Nair Alex Murison Laura Garcia-Prat Liran Shlush Rose Hurren Veronique Voisin Gary D. Bader Corey Nislow Mattias Rantalainen Soren Lehmann Mark Gower Cynthia J. Guidos Mathieu Lupien John E. Dick Mark D. Minden Aaron D. Schimmer Benjamin Haibe-Kains |
author_sort |
Arvind Singh Mer |
title |
Biological and therapeutic implications of a unique subtype of NPM1 mutated AML |
title_short |
Biological and therapeutic implications of a unique subtype of NPM1 mutated AML |
title_full |
Biological and therapeutic implications of a unique subtype of NPM1 mutated AML |
title_fullStr |
Biological and therapeutic implications of a unique subtype of NPM1 mutated AML |
title_full_unstemmed |
Biological and therapeutic implications of a unique subtype of NPM1 mutated AML |
title_sort |
biological and therapeutic implications of a unique subtype of npm1 mutated aml |
publisher |
Nature Portfolio |
publishDate |
2021 |
url |
https://doaj.org/article/a1a1fb4ad66d4a54b1ec1c09785a2551 |
work_keys_str_mv |
AT arvindsinghmer biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT emilymheath biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT seyedalimadanitonekaboni biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT nergizdoganartun biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT sisirakadambatnair biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT alexmurison biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT lauragarciaprat biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT liranshlush biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT rosehurren biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT veroniquevoisin biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT garydbader biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT coreynislow biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT mattiasrantalainen biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT sorenlehmann biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT markgower biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT cynthiajguidos biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT mathieulupien biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT johnedick biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT markdminden biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT aarondschimmer biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml AT benjaminhaibekains biologicalandtherapeuticimplicationsofauniquesubtypeofnpm1mutatedaml |
_version_ |
1718396548761518080 |